HLA Binding Prediction: How Alithea Bio Outperforms MHCflurry 2.0

Ovarian Cancer Awareness: Alithea Bio’s Commitment on WOCD 2026

Dark Proteome Unlocked: HLA-Compass AI Finds 17,082 Cancer Targets

Alithea Bio to Present HLA-Compass AI Breakthroughs at CIMT 2026 in Mainz

5 Key Advancements in Cervical Carcinoma Research via the HLA-Compass Database

Alithea Biotechnology is pleased to announce our participation in the German Biotech Days (Deutsche Biotechnologietage), taking place on April 22–23 in Leipzig.

Alithea Bio joins Berlin’s precision medicine ecosystem

Alithea Bio: Featured in smartXhealth Startup Spotlight

Advancing Immunopeptidomics: Highlights from the Boston Expert Session

Real-Time Immunopeptidomics: Accelerating Target Validation with HLA-Compass

4,000 Strong: Celebrating Our Growing Community in Precision Immunotherapy

Beyond Cancer: How Immunopeptidomics is Unlocking the Next Frontier in HIV Cure Research

Bridging the Gap Between AI and Immunity: Alithea Bio Named UN AI for Good Finalist

Advancing Immunopeptidomics: Meet the Experts Behind the Conference

Alithea Bio at IO360° 2026: Showcasing Novel Immunopeptidomics Technologies

The Future of Neoantigen Discovery: Trends and Challenges

Off-Target Toxicity in Immunotherapy: Identification and Mitigation Strategies

Mass Spectrometry vs. NGS for HLA Peptide Analysis:Pros and Cons

HLA Peptide Characterization: The Key to Safer TCR Therapies

How Immunopeptidomics is Revolutionizing Cancer Immunotherapy

The Complete Guide to Immunopeptidomics: From Workflow Optimization to Biologics Testing

Breaking the Silence: Alithea Bio and CHOP Unveil “HLA-Shuttle” to Target Immunologically Cold Tumors

Is Multiantigen T-Cell Therapy the Future of Pancreatic Cancer Care?

The Double Agent: Soluble HLA as a Master Regulator of Immunity

The Hidden Repertoire: Neoself-Antigens in Lupus and Cancer

Breaking Tolerance: Can We Successfully Target Self-Antigens Without Unmanageable Toxicity?

Personalized TCR Therapy: From “Impossible” to Proven in Nature Medicine

The Trap in the Microenvironment: Why TAMs are the Real Drivers of T-Cell Exhaustion

Engineering Out the Immune Response: How Immunopeptidomics is De-Risking AAV Gene Therapy

From Heatmap to Safety Assessment: Rapid Off-Target Screening in HLA-Compass

Is HLA Allele Loss Overstated? Insights from 80k Patients

The Hierarchy of Healing: How mRNA Vaccines Shape T-Cell Fate

Heart of the Matter: Solving the Titin Toxicity Challenge in HLA-A*02:01 Immunotherapy

Alithea Bio Launches HLA-Compass Binding Prediction

HLA Profiling: Enhancing Precision in Immunopeptidomics and Immunotherapy

Immunopeptidomics Unlocks New Paths for mRNA Vaccine Design

Alithea Bio to Participate at BIO-Europe 2025

Alithea Bio at CHI’s 17th Annual Immunogenicity & Bioassay Summit – Alexandria, VA, Oct 7–10, 2025

Alithea Bio at the Festival of Biologics 2025

🏆 Alithea Bio Wins Freiburger Innovationspreis 2025 for HLA‑Compass

Alithea Bio at #BayOConnect2025: Let’s Shape the Future of Immunotherapy

Alithea Bio attending the 8th International Neoantigen Summit

Webinar Recap: How HLA-Compass is Transforming Immunopeptidomics for Safer, Faster Immunotherapy

Alithea Bio zu Gast bei der Meisterklasse von Gründermotor

Die Investment Readiness Meisterklasse ist ein 5-wöchiges Accelerator-Programm des Gründermotors. Das Ziel ist Startups, die in den nächsten 3-6 Monaten…

13.02.2024 PRESS RELEASE

Freiburg/Oxford: Alithea Bio is thrilled to announce a strategic collaboration with Exogene, co-funded by the German ZIM and Innovate UK, combining our expertise to…